Compare Freshworks Inc (FRSH) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Freshworks Inc trades at $13.72 (market cap $3.57B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Freshworks Inc is far larger — about 3.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Freshworks Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FRSH | MRVI | |
|---|---|---|
Market Cap | $3.57B | $977.37M |
Volume | 4,701,335 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $13.92 | $9.00 |
52-Week Low | $6.88 | $2.83 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.94B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.90, down 0.14% with a bullish technical outlook. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains strong at 16% YoY, with improving margins and positive cash flow trends. Analyst consensus is evenly split between Buy and Hold ratings with a $14.60 price target.
FRSH presents a compelling growth story with accelerating profitability and AI-driven product expansion. Key risks include competitive pressures in the SaaS sector and execution challenges in enterprise market penetration. The stock's current valuation at 22x P/E appears reasonable given the company's growth trajectory and improving financial metrics.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
